MRC Global Announces Second Quarter 2023 Results
07 août 2023 16h15 HE
|
MRC Global
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- MRC Global Inc. (NYSE: MRC), the leading global distributor of pipe, valves, fittings and infrastructure products and services to diversified energy,...
MRC Global Announces First Quarter 2023 Results
08 mai 2023 16h15 HE
|
MRC Global
HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- MRC Global Inc. (NYSE: MRC), the leading global distributor of pipe, valves, fittings and infrastructure products and services to diversified energy,...
MRC Global Reports Full Year and Fourth Quarter 2022 Results and 2023 Outlook
13 févr. 2023 16h15 HE
|
MRC Global
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- MRC Global Inc. (NYSE: MRC), the leading global distributor of pipe, valves and fittings (PVF) and other infrastructure products and services to...
Magna Announces Fourth Quarter 2022 Results and 2023 Outlook
10 févr. 2023 05h00 HE
|
Magna International Inc.
Fourth Quarter 2022 Highlights Sales increased 5% to $9.6 billionExcluding foreign currency translation sales increased 13%, compared to a global light vehicle production increase of 5%Diluted...
Magna Announces Date for Q4 & Year End 2022 Results and 2023 Outlook Conference Call
10 janv. 2023 16h58 HE
|
Magna International Inc.
AURORA, Ontario, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA) MAGNA ANNOUNCES DATE FOR Q4 & YEAR END 2022 RESULTS and 2023 OUTLOOK CONFERENCE CALL FRIDAY –...
Travere Therapeutics Provides Corporate Update and 2023 Outlook
09 janv. 2023 07h00 HE
|
Travere Therapeutics, Inc.
Company well-positioned for potential FDA Subpart H approval and commercial launch of sparsentan for IgA nephropathy (IgAN) in 1Q23, followed by potential EMA approval in second half of 2023 ...
VIRBAC : Perspectives 2023
19 déc. 2022 02h30 HE
|
Virbac
Alors que nous poursuivons l'exécution de notre plan stratégique 2030, nous avons pris la décision de continuer d'accélérer en 2023 sur deux dimensions clés : la R&D et les investissements. Afin...
VIRBAC : 2023 Outlook
19 déc. 2022 02h30 HE
|
Virbac
As we continue to execute our 2030 strategic plan, we have made the decision to continue to accelerate in 2023 on two key dimensions : R&D and capital expenditures. In order to maximize the...